Join Medical Chronicle for a free, one-hour webinar on Parafengen IV: Unlocking synergy- fusing the power of paracetamol & Ibuprofen the ultimate blend for pain relief. This webinar is sponsored by Acino.
Join Medical Chronicle for a free, one-hour, webinar on Parafengen IV: Unlocking synergy- fusing the power of paracetamol & Ibuprofen the ultimate blend for pain relief. This webinar is sponsored by Acino.
Date: 12 June 2024
Time: 7:00pm
Topic: Parafengen IV: Unlocking synergy- fusing the power of paracetamol &Ibuprofen the ultimate blend for pain relief
Speakers: Dr Erni Welch, Dr Hartley Atkinson
Bios
Dr Erni Welch obtained his MBBCh at the University of the Witwatersrand. He then specialised in Anaesthesiology on the WITS Anaesthesia circuit whereafter he took up a consultant post at Baragwanath Hospital. In 2003 he joined the Dunkeld Practice. Erni has been a feature of academic anaesthesia in South Africa and Johannesburg for many years. He has been a convenor examiner for the Fellowship Part 1 exams, and has been intimately involved in Part 1 teaching on the WITS Circuit and at various Refresher Courses. He is the chair of the Anaesthetic Foundation which runs academic meetings in Johannesburg yearly. He co-authored Applied Pharmacology in Anaesthesiology and Critical Care with Prof Analee Milner, which has become a staple text of Pharmacology. He is passionate about pharmacology and Intravenous anaesthesia techniques and has lectured widely on these topics.
Dr Hartley Atkinson is a Pharmacologist and registered pharmacist who has a Masters of Pharmaceutical Chemistry with distinction and Doctorate in Pharmacology from Otago University, New Zealand. He has published over 30 research papers [including the world leading New England Journal of Medicine] and 2 book chapters. Hartley was previously Medical Director for Roche New Zealand and left to found, with his wife Marree, AFT Pharmaceuticals 25 years ago which is now listed on the Australian and New Zealand stock exchanges. AFT Pharma undertakes extensive drug development work to repurpose existing drugs for the treatment of various medical conditions such as Maxigesic which avoids the need for opioids.
Other examples of R&D projects include treatments for Burning Mouth Syndrome, Port Wine Stains, Strawberry Birthmarks, Keloid Scars, Vulva Lichen Sclerosis and Antibiotic Resistant Eye Infections. Its R&D based products are presently sold in over 70 countries around the globe with regulatory approvals across EU and USA.
